These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. De Martino MC; van Koetsveld PM; Feelders RA; Sprij-Mooij D; Waaijers M; Lamberts SW; de Herder WW; Colao A; Pivonello R; Hofland LJ Endocr Relat Cancer; 2012 Jun; 19(3):351-64. PubMed ID: 22420007 [TBL] [Abstract][Full Text] [Related]
26. Interferon-β is a potent inhibitor of cell growth and cortisol production in vitro and sensitizes human adrenocortical carcinoma cells to mitotane. van Koetsveld PM; Vitale G; Feelders RA; Waaijers M; Sprij-Mooij DM; de Krijger RR; Speel EJ; Hofland J; Lamberts SW; de Herder WW; Hofland LJ Endocr Relat Cancer; 2013 Jun; 20(3):443-54. PubMed ID: 23507702 [TBL] [Abstract][Full Text] [Related]
27. Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. Cusato J; De Francia S; Allegra S; Carrella S; Pirro E; Piccione FM; De Martino F; Ferrero A; Daffara FC; Terzolo M; Berruti A; Di Carlo F; Tampellini M; D'Avolio A J Pharm Pharmacol; 2017 Nov; 69(11):1524-1530. PubMed ID: 28809444 [TBL] [Abstract][Full Text] [Related]
28. Association of mitotane with chylomicrons and serum lipoproteins: practical implications for treatment of adrenocortical carcinoma. Kroiss M; Plonné D; Kendl S; Schirmer D; Ronchi CL; Schirbel A; Zink M; Lapa C; Klinker H; Fassnacht M; Heinz W; Sbiera S Eur J Endocrinol; 2016 Mar; 174(3):343-53. PubMed ID: 26671975 [TBL] [Abstract][Full Text] [Related]
30. Roles of the pathologist in evaluating surrogate markers for medical therapy in adrenocortical carcinoma. Sasano H; Satoh F; Nakamura Y Endocr Pathol; 2014 Dec; 25(4):366-70. PubMed ID: 25252621 [TBL] [Abstract][Full Text] [Related]
31. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model. Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475 [TBL] [Abstract][Full Text] [Related]
32. A fly in the ointment: reassessing mitotane's role in the treatment of adrenocortical carcinoma. Bapat AA; Demeure MJ; Bussey KJ Pharmacogenomics; 2012 Aug; 13(11):1207-9. PubMed ID: 22920388 [No Abstract] [Full Text] [Related]
33. Modulation of proteomic profile in H295R adrenocortical cell line induced by mitotane. Stigliano A; Cerquetti L; Borro M; Gentile G; Bucci B; Misiti S; Piergrossi P; Brunetti E; Simmaco M; Toscano V Endocr Relat Cancer; 2008 Mar; 15(1):1-10. PubMed ID: 18310271 [TBL] [Abstract][Full Text] [Related]
34. Functioning and nonfunctioning adrenocortical carcinoma: clinical presentation and therapeutic strategies. Demeure MJ; Somberg LB Surg Oncol Clin N Am; 1998 Oct; 7(4):791-805. PubMed ID: 9735134 [TBL] [Abstract][Full Text] [Related]
35. Practical treatment using mitotane for adrenocortical carcinoma. Terzolo M; Zaggia B; Allasino B; De Francia S Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):159-65. PubMed ID: 24732405 [TBL] [Abstract][Full Text] [Related]
36. High-dose mitotane strategy in adrenocortical carcinoma: prospective analysis of plasma mitotane measurement during the first 3 months of follow-up. Mauclère-Denost S; Leboulleux S; Borget I; Paci A; Young J; Al Ghuzlan A; Deandreis D; Drouard L; Tabarin A; Chanson P; Schlumberger M; Baudin E Eur J Endocrinol; 2012 Feb; 166(2):261-8. PubMed ID: 22048971 [TBL] [Abstract][Full Text] [Related]
37. How close are we to personalized mitotane dosing in the treatment of adrenocortical carcinoma? State of the art and future perspectives. Steenaard RV; Ettaieb MHT; Kerkhofs TMA; Haak HR Expert Opin Drug Metab Toxicol; 2021 Jun; 17(6):677-683. PubMed ID: 33886381 [TBL] [Abstract][Full Text] [Related]
38. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study. Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907 [TBL] [Abstract][Full Text] [Related]
39. Ovarian cyst formation in women of reproductive age receiving mitotane as part of the treatment of adrenocortical carcinoma: Clinical and experimental observations. Abrahamsson G; Ekerhovd E; Janson PO; Jansson S; Ahlman H; Wängberg B; Norström A Acta Obstet Gynecol Scand; 2020 Oct; 99(10):1297-1302. PubMed ID: 32282928 [TBL] [Abstract][Full Text] [Related]
40. Contribution of Therapeutic Monitoring in the Assessment of Toxic Adverse Effects of Mitotane: a Case Report. Jebabli N; Gaïes E; Eljebari H; Charfi R; Lakhal M; Klouz A; Salouage I; Trabelsi S Therapie; 2015; 70(6):545-6. PubMed ID: 26242497 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]